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A B S T R A C T
Background
Trigger finger is a disease of the tendons of the hand leading to triggering (locking) of affected fingers, dysfunction and pain. Available
treatments include local injection with corticosteroids, surgery, or splinting.
Objectives
To summarize the evidence on the efficacy and safety of corticosteroid injections for trigger finger in adults using the following endpoints:
treatment success, frequency of triggering or locking, functional status of the affected fingers, and severity of pain of the fingers.
Search methods
The databases CENTRAL, DARE, MEDLINE (1966 to November 2007), EMBASE (1956 to November 2007), CINAHL (1982 to
November 2007), AMED (1985 to November 2007) and PEDro (a physiotherapy evidence database) were searched.
Selection criteria
We selected randomized and controlled clinical trials evaluating efficacy and safety of corticosteroid injections for trigger finger in
adults.
Data collection and analysis
The databases were searched for titles of eligible studies. After screening abstracts of these studies, full text articles of studies which
fulfilled the selection criteria were obtained. Data were extracted using a predefined electronic form. The methodological quality of
included trials was assessed by using items from the checklist developed by Jadad and theDelphi list.We planned to extract data regarding
information on the primary outcome measures: treatment success, frequency of triggering or locking, and functional impairment of
fingers, severity of the trigger finger; and the secondary outcome measures: proportion of patients with side effects, types of side effects,
and patient satisfaction with injection.
Main results
Two randomized controlled studies were found that involved 63 participants: 34 were allocated to corticosteroids and lidocaine, and 29
were allocated to lidocaine alone. Corticosteroid injection with lidocaine was more effective than lidocaine alone on treatment success
at four weeks (relative risk 3.15, 95% CI 1.34 to 7.40). The number needed to treat to benefit was 3. No adverse events or side effects
were reported.
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Authors’ conclusions
The effectiveness of local corticosteroid injections was studied in only two small randomized controlled trials of poor methodological
quality. Both studies showed better short-term effects of corticosteroid injection combined with lidocaine compared to lidocaine alone
on the treatment success outcome. In one study the effects of corticosteroid injections lasted up to four months. No adverse effects were
observed. The available evidence for the effectiveness of intra-tendon sheath corticosteroid injection for trigger finger can be graded as
a silver level evidence for superiority of corticosteroid injections combined with lidocaine over injections with lidocaine alone.
P L A I N L A N G U A G E S U M M A R Y
Local corticosteroid injection for trigger finger
This summary of a Cochrane review presents what we know from research about the effect of corticosteroid injection for trigger finger.
Pain and symptoms of people with trigger finger may improve with a corticosteroid injection.
What is trigger finger and corticosteroid injection?
Trigger finger is a disease of the tendons of the finger, which makes the finger difficult to straighten. It causes snapping or locking of
the affected finger when flexing or stretching. Sometimes it can cause the hand to become painful.
Corticosteroid injections are shots with a needle into a joint (such as your finger) or a tendon. Corticosteroids work by reducing the
inflammation of the finger. The injection itself might also help to relieve the pressure on the tendon.
Best estimate of what happens after a corticosteroid injection:
37 out of 100 people benefited from corticosteroid injection combined with a painkiller; compared to 17 out of 100 people who
benefited following injection with a painkiller only.
B A C K G R O U N D
Trigger finger (also known as stenosing tenosynovitis) is a condi-
tion that causes triggering, snapping, or locking on flexion of the
involved finger. Entrapment of the affected tendon results in diffi-
culty in flexing or extending the finger and is frequently associated
with pain in the palm of the hand.
Notta reported the first four cases attended by the physician Nela-
ton in 1850, and the first review of the literature on this subject
was published by Compere in 1933 (Moore 2000). From the mid-
1980s onwards, trigger finger has been suggested to fall under um-
brella terms such as ’repetitive strain injury’ (RSI) and ’cumulative
trauma disorder’. A study of 665 workers at a meat packing plant
reported a point prevalence of 14%, suggesting a relation between
occupation and trigger finger (Gorsche 1998), although a study
by Trezies 1998 could not confirm this association.
The flexor tendon sheath in the finger is a double-walled, connec-
tive tissue cylinder that is held in place by five ring-shaped and
three cross-shaped pulleys (Figure 1). The triggering phenomenon
is caused by incompatibility between the tendon and its sheath,
most probably due to thickening of the first annular pulley. On
histologic examination the pulley shows fibrous and cartilaginous
tissue changes that include the presence of chondrocytes and gly-
cosaminoglycans (mucopolysaccharide) and degenerative changes.
These changes are believed to represent adaptations to shear load.
Although trigger finger is also known as tenosynovitis, no inflam-
matory changes were seen in the histologic studies (Moore 2000).
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Figure 1. The flexor tendon sheath in the finger
There is no universally agreed case definition for trigger finger and
the diagnosis is made by history and physical examination; there
are no specific diagnostic tests. Laboratory tests and radiographic
examination techniques are not indicated, unless an underlying
cause is suspected (for example infection).
The lifetime prevalence of trigger finger among a group of non-
diabetics above the age of 30 years has been estimated at 2.2%.
Generally the condition is more common among women than
men, and the age distribution is bimodal with one group below
six years of age and the other above 40 years of age (most of the
affected individuals are in the fifth or sixth decade of their life).
Most cases involve a single finger; some have multiple affected
fingers and people with multiple affected fingers at presentation
are three times more likely to have a subsequent finger affected.
Among people without concurrent disease the thumb is the most
commonly affected finger, followed by the ring finger and the little
finger. The right hand is themost frequently affected. Spontaneous
recovery has been reported in 20% to 29% of cases of trigger finger
(Moore 2000).
Trigger finger occurs more commonly in patients with diabetes
mellitus (probably due to glucose-induced collagen modifica-
tions), carpal tunnel syndrome, Dupuytren’s disease, rheumatoid
arthritis, amyloidosis, hypothyroidism, mucopolysaccharide stor-
age disorders, and congestive heart failure (Blyth 1996; Chammas
1995). A separate entity is formed by trigger finger in children,
which is a rare disease (0.3% of newborns) where almost always
the thumb is affected and the predominant symptom is limited
extension (Rodgers 1994; van den Borne 2000).
Available treatment modalities for trigger finger are operative
(open or percutaneous surgical division of the A1 pulley) and
non-operative (corticosteroid injections and splinting). The per-
centages of participants with trigger finger treated by operation,
steroid injection, and splinting are not known. Operative ther-
apy seems to be effective with cure rates of 89% to 97% in non-
randomised studies but it is associated with higher cost, longer
absence from work, and the possibility of surgical complications
(Turowski 1997). An explanation for the presumed efficacy of lo-
cal corticosteroid injections could be that the anti-inflammatory
effect reduces the swelling of the A1 pulley (although in histo-
logical studies, as mentioned above, inflammation in the affected
tissues could not be demonstrated). Corticosteroid injection has
been assumed to be as effective as surgical therapy, with reported
cure rates ranging from 60% to 92% (Moore 2000), but there
are no studies that compared corticosteroid injections directly to
surgical treatment . Splinting appeared to be effective in in 70%
of cases compared with 82% receiving an injection (Patel 1992).
There have been no reports of serious complications of injection
therapy, but possible side effects could be steroid flare, tendon-
ruptures, local infection, allergic reactions to corticosteroids, and
atrophy of subcutaneous fat tissue.
Trigger finger appears to be a fairly common disorder leading to
marked discomfort and dysfunction of the hand. Injection with
corticosteroids has been suggested to be effective and safe; com-
pared with surgical therapy, it also seems more easy to apply and
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cost efficient. Therefore, we decided to perform a systematic re-
view on the effectiveness and safety of corticosteroid injections for
trigger fingers in adults.
O B J E C T I V E S
Our objective was to systematically review the evidence from clin-
ical trials on the efficacy and safety of corticosteroid injections for
trigger finger in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomized controlled trials (RCTs) and controlled clinical
trials evaluating local injection with corticosteroids were included
in this review.
Types of participants
Only studies of adult populations (older than 18 years) with a clin-
ical diagnosis of trigger finger (triggering with or without locking
of a finger or pain at the A1 pulley) and irrespective of the dura-
tion of symptoms were included. Studies addressing treatment of
trigger finger of infectious origin were excluded.
Types of interventions
All studies using injectable corticosteroids as treatment were in-
cluded: any volume, type, and concentration of corticosteroid
used; whether a local anaesthetic agent was added or not; and re-
gardless of the injection technique. Studies comparing corticos-
teroid injection to placebo injection, injection with local anaes-
thetic, injection with a different type of steroid, splinting, sys-
temic analgesics including non-steroidal anti-inflammatory drugs
(NSAIDs), systemic steroids, surgery, combination treatments, or
no intervention were included.
Types of outcome measures
Primary:
• treatment success, yes or no (definition of treatment success
may vary across trials);
• frequency of triggering or locking of the affected fingers;
• functional status of the finger (using validated instruments
to measure hand function, e.g. arthritis impact measurement
scale);
• severity of pain or tenderness at the base of the digit on the
palm of the hand;
• proportion of patients with side effects of steroid injection.
Secondary:
• patient satisfaction (using validated questionnaires).
Search methods for identification of studies
The following electronic databases were searched:
• CENTRAL (The Cochrane Library);
• MEDLINE (Ovid platform) (1966 to November 2007);
• EMBASE (Ovid platform) (1956 to November 2007);
• CINAHL (Ovid platform) (1982 to November 2007);
• AMED (Ovid platform) (1985 to November 2007);
• PEDro (the physiotherapy evidence database);
• DARE (The Database of Abstracts of Reviews of
Effectiveness);
• Dissertation abstracts.
The search strategy was developed for MEDLINE and modified
as necessary for the other databases.
Complete search strategies for each database are provided in
Appendix 1; Appendix 2; Appendix 3; Appendix 4; Appendix 5;
Appendix 6; Appendix 7; Appendix 8. The references of all rel-
evant publications (RCTs and reviews) were checked to identify
additional trials. Content experts were contacted for unpublished
data. There were no language restrictions.
Data collection and analysis
Selection of studies
Two review authors independently selected trials for inclusion in
this review, based on the content of the title and abstracts obtained
through electronic searching of the databases. Each review author’s
selection was compared. Any discrepancies in opinion about eli-
gibility of a trial were resolved by discussion and consensus by the
two review authors.
Quality appraisal
Two review authors independently extracted all data. Each trial
was assessed by using a combination of an established quality as-
sessment tool developed by Jadad (Jadad 1996) and the Delphi
list (Verhagen 1998). The quality items assessed were:
1. randomization;
2. concealment of allocation;
3. blinding of outcome assessor, care provider, and patient;
4. reporting of withdrawals and dropouts;
5. similarity of groups at baseline regarding most important prog-
nostic indicators;
6. specification of eligibility criteria;
7. availability of point estimates and measures of variability of
primary outcome measures;
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8. use of intention-to-treat analysis.
Each criterion was rated as positive, negative, or inconclusive (if
insufficient information was presented).
Data extraction
Details regarding the study population, interventions, treatment
periods, length of follow up, complications, baseline demographic
data, and baseline and end of study outcome measures were ex-
tracted using a pre-defined electronic form, by two review authors.
Short-term outcomes were arbitrarily defined as outcomes up to
three months after the intervention and long-term outcomes as
outcomes one year post-intervention, or later. Referring back to
the original article and establishing consensus resolved differences
in data extraction. A third review author was consulted to help
resolve differences.
Analysis
For continuous data, weighted mean differences (MD) were
planned to be calculated for outcomes measured using the same
scale; and when the same outcomes were measured using differ-
ent scales, standardized mean differences (SMD) were to be used.
Absolute and relative differences in the change from baseline were
to be calculated for continuous outcomes. Absolute benefit was to
be calculated as the improvement in the treatment group minus
the improvement in the control group, in original units. Relative
difference in the change from baseline was to be calculated as the
absolute benefit divided by the baseline mean.
For dichotomous data the results for each study were presented as
relative risk and the number needed to treat (NNT).
Heterogeneity
To assess heterogeneity of trial results the Cochrane Chi2 test and
I2 statistic were planned to be used. In case of significant statis-
tical heterogeneity potential sources were planned to be explored
by subgroup analysis. Since clinical and methodological diver-
sity always occur in a meta-analysis, statistical heterogeneity is in-
evitable (Higgins 2003). The test for heterogeneity is irrelevant to
the choice of analysis; accordingly the random-effects model was
used by default as it is identical to the fixed-effect model if there
is no heterogeneity (I2 = 0%). In order to assess and quantify the
possible magnitude of inconsistency (that is heterogeneity) across
studies, we used I2 with a rough guide for interpretation as follows:
0% to 40% might not be important; 30% to 60% may represent
moderate heterogeneity; 50% to 90% may represent substantial
heterogeneity; 75% to 100% shows considerable heterogeneity.
Subgroup analysis
Subgroup analysis was planned in regard to the following aspects:
• ’idiopathic’ or trigger finger secondary to diabetes;
• duration of symptoms at baseline, short if symptoms were
present for up to four weeks, intermediate if symptoms were
present for one month to one year, and long if symptoms were
present for one year or longer.
• trial design, RCT or controlled clinical trial.
Clinical relevance tables
Clinical relevance tables were compiled for primary outcomes un-
der the ’Additional tables’ to improve the readability of the review.
For dichotomous outcomes, the weighted absolute risk difference
was calculated using the risk difference (RD) statistic in RevMan.
RR-1 calculates the weighted relative per cent change. The num-
ber needed to treat (NNT) was calculated from the control group
event rate (unless the population event rate was known), and the
relative risk using the Visual Rx NNT calculator (Cates 2004).
This was done for the primary outcomes measured.
Continuous outcome tables were also planned to be presented.
Weighted absolute change was planned to be calculated from the
weightedmean difference (WMD) statistic in RevMan when trials
using the same scale were pooled. For outcomes pooled on differ-
ent scales, the standardized mean difference (SMD) was planned
to be multiplied by the baseline standard deviation in the control
group to obtain the weighted absolute change. Relative per cent
change from baseline was planned to be calculated as the absolute
benefit divided by the baseline mean of the control group. NNT
was planned to be calculated using theWells calculator available at
the Cochrane Musculoskeletal Group editorial office. The mini-
mal clinically important difference (MCID) for each outcome was
planned to be determined for input into the calculator.
Grading of evidence
The evidence obtained in this systematic review was finally graded
according to conventions as proposed by the Cochrane Muscu-
loskeletal Group (Tugwell 2004).
Platinum: a published systematic review that has at least two in-
dividual controlled trials each satisfying the following.
Sample sizes of at least 50 per group: if these do not find a sta-
tistically significant difference, they are adequately powered for a
20% relative difference in the relevant outcome.
Blinding of patients and assessors for outcomes.
Handling of withdrawals > 80% follow up (imputations based
on methods such as ’last observation carried forward’ (LOCF) are
acceptable).
Concealment of treatment allocation.
Gold: at least one RCT meeting all of the following criteria for
the major outcome(s) as reported.
Sample sizes of at least 50 per group: if these do not find a sta-
tistically significant difference, they are adequately powered for a
20% relative difference in the relevant outcome.
Blinding of patients and assessors for outcomes.
5Corticosteroid injection for trigger finger in adults (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Handling of withdrawals > 80% follow up (imputations based on
methods such as LOCF are acceptable).
Concealment of treatment allocation.
Silver: a systematic review or randomized trial that does not meet
the above criteria. Silver ranking would also include evidence from
at least one study of non-randomised cohorts that did and did not
receive the therapy, or evidence from at least one high quality case-
control study. A randomized trial with a ’head-to-head’ compar-
ison of agents would be considered silver level ranking unless a
reference were provided to a comparison of one of the agents to
placebo showing at least a 20% relative difference.
Bronze: the bronze ranking is given to evidence if at least one
high quality case series without controls (including simple before
and after studies in which patients act as their own control) or if
the conclusion is derived from expert opinion based on clinical
experience without reference to any of the foregoing (for example,
argument from physiology, bench research, or first principles).
This review will be updated two years after publication.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Our search resulted in 230 titles from a combined search inMED-
LINE, EMBASE, AMED and CINAHL. No titles were found
in PEDro, CENTRAL, DARE, and Dissertation abstracts. Af-
ter screening the titles and abstracts, 16 possible studies were se-
lected for further evaluation (Anderson 1991; Benson 1997; Boyer
2004; Clark 1973; Kraemer 1990; Lambert 1992; Lopez 1991;
Maneerit 2000; Maneerit 2003; McGrath 1984; Murphy 1995;
Patel 1992; Patel 1997; Povlsen 2004; Stratz 2002; Taras 1998).
After retrieving full text articles of these 16 reports, six appeared to
be non-randomized (Anderson 1991; Benson 1997; Clark 1973;
Kraemer 1990; Patel 1992; Patel 1997), three did not study trig-
ger finger (Lopez 1991; Povlsen 2004; Stratz 2002), three did not
study one of the comparisons of interest as two compared operative
treatment (percutaneous release) preceded by steroid injection to
steroid injection alone (Maneerit 2000; Maneerit 2003) and one
compared intra-sheath injection to subcutaneous injection (Taras
1998). Of the remaining two studies, one was a review article
(McGrath 1984) and one a comment on a reported trial (Boyer
2004). The 14 excluded trials, and details of why they failed to
meet the inclusion criteria for this review, are outlined in the table
’Characteristics of excluded studies’.
We were also aware of an ongoing randomised controlled trial
assessing effectiveness of corticosteroid injections in the setting of
primary care, but the results of the study were not published yet
when our search was performed (see Characteristics of ongoing
studies).
The two included studies were controlled trials comparing the ef-
ficacy of steroid injection with lidocaine injections in the setting
of secondary care. One included 41 fingers of 41 participants with
a diagnosis of trigger finger (two participants were lost to follow
up therefore only 39 participants were included in the analysis)
and compared the effectiveness of injection of methylprednisolone
(0.5 ml) combined with 1% lidocaine (0.5 ml) to 1% lidocaine
alone (Lambert 1992). Treatment success in this study (defined
as complete resolution of symptoms or sufficiently improved that
further treatment was not necessary) was assessed one month af-
ter injection. The second study included 24 fingers in 24 par-
ticipants and compared the effectiveness of betamethasone (1ml)
combined with lidocaine (3 ml) to injection with 1% lidocaine
(4 ml) alone. Treatment success (defined as participants becoming
asymptomatic) was assessed immediately after injection, and three
weeks and four months after injection (Murphy 1995). A detailed
description of the two included studies can be found in the table
’Characteristics of included studies’.
Risk of bias in included studies
Randomization
Both studies used pseudo-randomization, either allocating pa-
tients based on date of birth (Lambert 1992) or on day of presen-
tation (Murphy 1995).
Allocation concealment
Both reports did not mention how allocation concealment was
realized.
Participant flow and follow up
In the study by Lambert 1992 41 participants were enrolled and
randomized: 20 participants were allocated to steroid injection,
21 participants allocated to lidocaine injection; all participants re-
ceived the allocated intervention; and two participants in the lido-
caine group were lost to follow up and excluded from the analysis.
In the study by Murphy 1995 24 participants were enrolled and
randomised: 14 participants were allocated to steroid injection, 10
participants were allocated to lidocaine injection; all participants
received the allocated intervention and were analysed since none
of the enrolled cases were lost to follow up.
Summary of quality items
In the study by Lambert 1992 the outcome assessor was blinded,
there was reporting of withdrawals and dropouts, eligibility criteria
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were specified, and point estimates and measures of variability of
primary outcome measures were available. However, concealment
of allocation, blinding of care provider, blinding of patients, and
similarity of groups at baseline regarding most important prog-
nostic indicators were unclear and no intention-to-treat analysis
was used.
In the Murphy 1995 study the outcome assessor and patient were
blinded, but the care provider was not. Withdrawals and drop-
outs were reported, an intention-to treat analysis was used, but no
concealment of allocation was used. It was unclear whether the
two treatment groups were similar at baseline regarding the most
important prognostic indicators, and whether point estimates and
measures of variability of primary outcomes were available (Table
1).
Other shortcomings
Both trials did not specify which specific diagnostic criteria were
used for the diagnosis of trigger finger, how many cases were as-
sessed for eligibility prior to enrolment; and insufficient informa-
tion of baseline demographic and clinical characteristics was pro-
vided to make a judgement about comparability of corticosteroid
and control groups.
For further details see the table of ’Characteristics of included
studies’ and ’Additional Table 1’ for methodological quality of
included studies.
Effects of interventions
The only primary outcome measure assessed in both studies was
the dichotomous outcome of treatment success. In the study by
Lambert 1992 this was defined as complete resolution of symp-
toms or sufficient improvement for further treatment to be unnec-
essary, and in the study by Murphy 1995 it was defined as being
asymptomatic. There were no data available regarding frequency
of triggering, severity of pain, and functional status of the hand.
Regarding secondary outcome measures, both studies stated that
there were no adverse reactions or complications (it was not clear
whether this was systematically assessed). Patient satisfaction with
treatment was not assessed in either study.
Because of the small number of studies and included patients, and
since the two included studies seemed homogenous, we refrained
from subgroup and sensitivity analyses.
In the study by Lambert 1992 treatment success assessed one
month after injection was 45% (9/20) in the methylprednisolone
+ lidocaine group and 16% (3/19) in the lidocaine alone group.
Absolute risk reduction was 0.292 (95% CI 0.017 to 0.567), rel-
ative risk 2.85 (95% CI 0.91 to 8.96) with a number needed to
treat (NNT) of 3 (95% CI 2 to 58).
In the study by Murphy 1995 treatment success assessed three
weeks after injection therapy was 71% (10/14) in the betametha-
sone + lidocaine group and 20% (2/10)in the lidocaine alone
group. Absolute risk reduction was 0.514 (95% CI 0.165 to
0.864), relative risk 3.57 (95% CI 0.99 to 12.88) with a NNT of
2 (95% CI 1 to 6).
Four months after injection therapy treatment success was 64%
(9/14) in the betamethasone + lidocaine group and 20% (2/10) in
the lidocaine alone group, absolute risk reduction 0.514 (95% CI
0.165 to 0.864), relative risk 3.21v(95% CI 0.88 to 11.79), and
the NNT was 2 (95% CI 1 to 6).
Pooling of the two studies resulted in a total of 63 participants.
Corticosteroid injectionswith lidocaine showed significantlymore
effectiveness within four weeks than lidocaine injection alone (RR
3.15, 95% CI 1.34 to 7.40). The control event rate was 17.2 %
for the pooled group, the weighted absolute risk difference was
38% (95% CI 16 to 59) and the NNT was 3 (95% CI 2 to 18)
(Table 2).
Thus, our data indicated that an expected additional 37 out of
100 participants benefited from the combination of lidocaine and
steroid injection; opposed to 17 patients who benefited following
(control) therapy with lidocaine only (Figure 2).
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Figure 2.
D I S C U S S I O N
In this review, including two randomized controlled trials (RCTs)
with a total of 63 participants (Lambert 1992; Murphy 1995), we
found silver level evidence for superiority of intra-tendon sheath
corticosteroid injections combined with lidocaine over injections
with lidocaine alone. In one of the included studies (Murphy 1995)
the effects of corticosteroid injections lasted up to four months.
Both studies did not report any adverse effects.
However, there were only two RCTs available which fulfilled the
inclusion criteria. The total number of participants included in
this review was small, thereby possibly reflecting publication bias.
Furthermore, the methodological quality of the two studies was
poor and there were some flaws in the quality of reporting.
Effectiveness (using treatment success as the outcome measure)
was consistent in the two included studies and the effect size was
considerable. We found that for effectiveness within four weeks
the relative risk was 3.15, and that the number needed to treat
(NNT) was 3; meaning that there is a 3.15 times greater proba-
bility of participants treated with local corticosteroid injection to
achieve treatment success than for participants treated with lido-
caine injection alone, and that three participants have to be treated
by local corticosteroid injection to achieve treatment success in
one extra participant. For effectiveness at four months (available
only for the 24 participants in the study by Murphy 1995) the
relative risk was 3.21 and the NNT was 2.
The two trials suggest that corticosteroid injection therapy is ef-
fective and safe for the treatment of trigger finger, but these effects
need to be confirmed in larger, well-designed randomized trials.
Several other questions remain to be answered. First, it is not
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clear whether injection therapy is superior to surgical treatment or
splinting, in efficacy or safety. Some retrospective studies have in-
vestigated the effectiveness of surgery, reporting treatment success
in 67% to 90% of the cases, but this has never been assessed in
RCTs and has never been compared directly to injection therapy
or splinting. Second, we do not know which diagnostic criteria
and outcome measures are valid to use for studies of interventions
for trigger finger. At this moment in time there is no universally
agreed case definition for trigger finger and there are no validated
instruments for measuring symptom severity and functional dis-
ability (ideally with known minimal clinically important differ-
ences). Third, the two trials analysed in this reviewwere performed
in the setting of secondary care and generalizability to other set-
tings (for example primary care) remains to be established. Finally,
this review suggests efficacy up to four months, but long-term ef-
ficacy still remains to be clarified.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is silver level evidence that corticosteroid injections are ef-
fective for the treatment of trigger finger, but the implications for
daily clinical practice may be limited by the fact that the evidence
we found is based on two small studies of poor quality, performed
in the setting of secondary care, and there were only data available
for effectiveness up to four months. However, corticosteroid in-
jection is an easily applicable treatment modality, not expensive,
and less invasive than surgery. Therefore, we feel that the initial
treatment for patients should be corticosteroid injection rather
than surgery. Other non-invasive interventions such as splinting
(which was not evaluated in this review) may also be appropriate
first-line interventions.
Implications for research
A case definition for trigger finger should be formulated for re-
search purposes. Validated and relevant outcomemeasures for trig-
ger finger should be developed. Future RCTs should have ade-
quate sample sizes, better methodological quality (especially ad-
equate randomization procedures and allocation concealment),
and the findings should be reported according to the CONSORT
statement. More comparison studies are needed, comparing corti-
costeroid injections to surgery and splinting; comparing different
types and dosages of corticosteroids; and effectiveness in differ-
ent types of healthcare settings (for example primary care). Future
studies should also address the natural course of trigger finger.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Lambert 1992
Methods Randomized controlled study: allocation of intervention based on date of birth.




Inclusion criteria: symptoms of trigger finger for at least 3 months.
Exclusion criteria: insulin dependent diabetes mellitus, rheumatoid arthritis, eczema, current infection or
previous injection in the past 3 months.
Mean age 54 years.
25 female, 16 male.




-20 fingers allocated to methylprednisolone injection, 21 to lidocaine injection
-41 fingers received allocated intervention
-lost to follow up: 2 fingers in the lidocaine group
-analysed: 20 fingers in steroid injection group, 19 fingers in lidocaine group
Interventions Group 1: 0.5 ml (20 mg) methylprednisolone
+ 0.5 ml 1% lidocaine.
Group 2: 1 ml 1% lidocaine.
Technique: intra-sheath injection.
Number of injections: 1.
Outcomes Assessment 1 month after injection.
Definition of treatment success: complete resolution of symptoms or sufficiently improved that further
treatment was not necessary.
Definition of treatment failure: persistent clicking or locking requiring retreatment
Notes
Risk of bias Risk of bias
Item Authors’ judgement Description
Allocation concealment? No B - Unclear
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Murphy 1995
Methods Randomized controlled study: allocation of intervention based on date of birth.




Inclusion criteria: primary trigger finger
Exclusion criteria: participants with rheumatoid arthritis, diabetes mellitus, prior damage of tendons,
prior diagnosis of trigger finger or locked finger.
Mean age: betamethasone+lidocaine group 54 years, lidocaine group: 62 years.




-14 fingers allocated to methylprednisolone injection, 10 to lidocaine injection
-24 fingers received allocated intervention
-lost to follow up: 0
-analysed: 14 fingers in steroid injection group, 10 fingers in lidocaine group
Interventions Group 1: 1 ml betamethasone + 3 ml 1% lidocaine.
Group 2: 4ml 1% lidocaine.
Technique: intra-sheath injection.
Number of injections: 1, re-injection after 3 weeks for unrelieved cases in Celestone+ lidocaine and
lidocaine alone group
Outcomes Assessment directly after injection, 3 weeks after injection and 4 months after injection.
Definition of treatment success: asymptomatic.
Definition of treatment failure: not asymptomatic.
Notes
Risk of bias Risk of bias
Item Authors’ judgement Description
Allocation concealment? No B - Unclear
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anderson 1991 not a randomized study: prospective cohort study
Benson 1997 not a randomized study: prospective cohort study
Boyer 2004 not a trial (commentary)
12Corticosteroid injection for trigger finger in adults (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Clark 1973 not a randomized study: retrospective cohort study
Kraemer 1990 not a randomized study: retrospective cohort study
Lopez 1991 not condition of interest: tendinitis of shoulder, elbow and thumb
Maneerit 2000 not comparison of interest: surgery plus steroid injection versus steroid injection alone
Maneerit 2003 not comparison of interest: surgery plus steroid injection versus steroid injection alone
McGrath 1984 not a trial (review article)
Patel 1992 not a randomized study: prospective cohort study
Patel 1997 not a randomized study: prospective cohort study
Povlsen 2004 not condition of interest: basal joint arthritis of the thumb
Stratz 2002 not condition of interest: bicipital of supraspinatus tendinitis, epicondylitis, bursitis trochanterica, pes anserinus
tendinitis
Taras 1998 not comparison of interest:: intra-sheath versus subcutaneous steroid injection
Characteristics of ongoing studies [ordered by study ID]
Peters 2007
Trial name or title The Groningen Hand and Wrist Injection Therapy Trial
Methods Randomized controlled study




Inclusion criteria: triggering or locking of a finger with or without pain and tenderness or swelling at the A1-
pulley
Exclusion criteria: less than18 years of age, presence of an absolute contraindication for corticosteroid injection,
prior treatment in the last six months with steroid injection and/ or surgery at the same anatomical location,
possible traumatic or neoplastic origin of symptoms, inability to fill in follow-up forms or absence of self
determination in the participant
Interventions Group 1: one or two injections of 1ml triamcinolonacetonide 10mg/ml
Group 2: one or two injections of 1ml 0,9 % NaCl
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Peters 2007 (Continued)
Outcomes 1. direct treatment response (consensus between physician and patient): no response; partial response, but
not satisfactory, warranting further treatment; partial response, satisfactory, not warranting further treatment;
complete resolution of symptoms and signs
2. perceived improvement (by patient): much worse, worse, not better/ not worse, better, much better
3.frequency of triggering: never, incidental, weekly, daily,always
4. pain and discomfort in the palm of the hand using a numerical rating scale: 0 = no pain to 10 = severe pain
5. Functional improvement using the sub items hand and finger function of the Dutch version of the second
version of the Arthritis Impact Measurement Scale (DUTCH AIMS-2)
Starting date 2003
Contact information Cyriac Peters-Veluthamaningal, general practitioner
Department of General Practice
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D A T A A N D A N A L Y S E S
Comparison 1. Corticosteroid + lidocaine injection versus lidocaine injection < 4 weeks




participants Statistical method Effect size
1 treatment success 2 63 Risk Ratio (M-H, Random, 95% CI) 3.15 [1.34, 7.40]
Comparison 2. Corticosteroid injection versus lidocaine injection at 4 months




participants Statistical method Effect size
1 treatment success @ 4 months 1 24 Risk Ratio (M-H, Random, 95% CI) 3.21 [0.88, 11.79]
Analysis 1.1. Comparison 1 Corticosteroid + lidocaine injection versus lidocaine injection < 4 weeks,
Outcome 1 treatment success.
Review: Corticosteroid injection for trigger finger in adults
Comparison: 1 Corticosteroid + lidocaine injection versus lidocaine injection < 4 weeks
Outcome: 1 treatment success








Lambert 1992 9/20 3/19 55.6 % 2.85 [ 0.91, 8.96 ]
Murphy 1995 10/14 2/10 44.4 % 3.57 [ 0.99, 12.88 ]
Total (95% CI) 34 29 100.0 % 3.15 [ 1.34, 7.40 ]
Total events: 19 (Treatment), 5 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.63 (P = 0.0085)
0.001 0.01 0.1 1 10 100 1000
Favours control Favours treatment
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Analysis 2.1. Comparison 2 Corticosteroid injection versus lidocaine injection at 4 months, Outcome 1
treatment success @ 4 months.
Review: Corticosteroid injection for trigger finger in adults
Comparison: 2 Corticosteroid injection versus lidocaine injection at 4 months
Outcome: 1 treatment success @ 4 months








Murphy 1995 9/14 2/10 100.0 % 3.21 [ 0.88, 11.79 ]
Total (95% CI) 14 10 100.0 % 3.21 [ 0.88, 11.79 ]
Total events: 9 (Treatment), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.76 (P = 0.078)
0.1 0.2 0.5 1 2 5 10
Favours control Favours treatment
A D D I T I O N A L T A B L E S
Table 1. Methodological quality of included studies
Quality Item Lambert Murphy
randomization no no
concealment of allocation no no
blinding of outcome assessor yes yes
blinding of care provider unclear no
blinding of patient unclear yes
reporting of withdrawals and dropouts yes yes
similarity of groups at baseline regarding
most important prognostic indicators
unclear unclear
specification of eligibility criteria yes no
availability of point estimates and measures
of variability of primary outcome measures
yes unclear
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Table 1. Methodological quality of included studies (Continued)
use of intention-to-treat analysis no yes
Table 2. Clinical relevance table: treatment success of steroid injection






































A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. exp fingers/
2. exp JOINTS/
3. exp Finger Joint/
4. 1 and 2
5. exp TENOSYNOVITIS/
6. exp Tendons, Para-Articular/
7. exp TENDINITIS/
8. exp Tendon Injuries/








17Corticosteroid injection for trigger finger in adults (Review)












28. (steroid$ adj2 inject$).tw.
29. or/18-29
30. 17 and 29
31. randomized controlled trial.pt.
32. controlled clinical trial.pt.
33. randomized controlled trials.sh.
34. random allocation.sh.
35. double blind method.sh.
36. single-blind method.sh.
37. or/31-36
38. (animal$ not human).sh.
39. 37 not 38
40. clinical trial.pt.
41. exp clinical trials/
42. (clin$ adj38 trial$).ti,ab.






49. 48 not 38
50. 49 not 39
51. comparative study.sh.
52. exp evaluation studies/
53. follow up studies.sh.
54. prospective studies.sh.
55. (control$ or prospectiv$ or volunteer$).ti,ab.
56. or/51-55
57. 56 not 38
58. 57 not (39 or 50)
59. 30 and 58
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Appendix 2. EMBASE search strategy
1. exp Finger/
2. exp JOINT/
3. exp Finger Joint/
4. 1 and 2
5. exp TENOSYNOVITIS/
6. exp TENDINITIS/



















26. (steroid$ adj2 inject$).tw.
27. or/16-26
28. 15 and 27
29. random$.ti,ab.
30. factorial$.ti,ab.
31. (crossover$ or cross over$ or cross-over$).ti,ab.
32. placebo$.ti,ab.
33. (doubl$ adj blind$).ti,ab.





39. double blind procedure.sh.
40. randomized controlled trial.sh.
41. single blind procedure.sh.
42. or/29-41
43. exp animal/ or nonhuman/ or exp animal experiment/
44. exp human/
45. 43 and 44
46. 43 not 45
47. 42 not 46
48. 28 and 47
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Appendix 3. CINAHL search strategy
1. exp fingers/
2. exp JOINTS/
3. exp Finger Joint/
4. 1 and 2
5. exp TENOSYNOVITIS/
6. exp TENDINITIS/
7. exp Tendon Injuries/



















27. (steroid$ adj2 inject$).tw.
28. or/17-27
29. 16 and 28
Appendix 4. AMED search strategy
1. exp fingers/
2. exp JOINTS/
3. exp Finger Joint/
4. 1 and 2
5. exp TENOSYNOVITIS/
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20. triamcinolone.tw.
21. (steroid$ adj2 inject$).tw.
22. or/15-21
23. 14 and 22
Appendix 5. PEDro search strategy
Search 1
Tenosynovitis in Abstract or title and Body Part = hand or wrist
Search 2
Tendon in Abstract or title and Body Part = hand or wrist
Search 3
Trigger or snapping or locking in Abstract or title
Appendix 6. CENTRAL search strategy
#1MeSH descriptor Fingers explode all trees
#2MeSH descriptor Joints explode all trees
#3MeSH descriptor Finger Joint explode all trees
#4(#1 AND #2)
#5MeSH descriptor Tenosynovitis explode all trees
#6MeSH descriptor Tendinopathy explode all trees
#7MeSH descriptor Tendon Injuries explode all trees








#16(#3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15)
#17MeSH descriptor Glucocorticoids explode all trees
#18 glucocorticoid*:ti,ab
#19MeSH descriptor Adrenal Cortex Hormones explode all trees
#20corticoster*:ti,ab
#21MeSH descriptor Methylprednisolone explode all trees
#22methylprednisolone:ti,ab
#23MeSH descriptor Betamethasone explode all trees
#24betamethasone:ti,ab
#25MeSH descriptor Triamcinolone explode all trees
#26triamcinolone:ti,ab
#27(steroid* near/2 inject*):ti,ab
#28(#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27)
#29(#16 AND #28)
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Appendix 7. DARE search strategy
1MeSH descriptor Fingers explode all trees
#2MeSH descriptor Joints explode all trees
#3MeSH descriptor Finger Joint explode all trees
#4(#1 AND #2)
#5MeSH descriptor Tenosynovitis explode all trees
#6MeSH descriptor Tendinopathy explode all trees
#7MeSH descriptor Tendon Injuries explode all trees








#16(#3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15)
#17MeSH descriptor Glucocorticoids explode all trees
#18 glucocorticoid*:ti,ab
#19MeSH descriptor Adrenal Cortex Hormones explode all trees
#20corticoster*:ti,ab
#21MeSH descriptor Methylprednisolone explode all trees
#22methylprednisolone:ti,ab
#23MeSH descriptor Betamethasone explode all trees
#24betamethasone:ti,ab
#25MeSH descriptor Triamcinolone explode all trees
#26triamcinolone:ti,ab
#27(steroid* near/2 inject*):ti,ab
#28(#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27)
#29(#16 AND #28)
Appendix 8. Dissertation abstracts search strategy
Search 1
Trigger finger OR trigger thumb OR trigger digit* OR locking finger OR locking thumb OR locking digit*
Search 2
(Tenosynovitis OR tendon*) AND (finger OR thumb OR digit*) AND (glucocorticoid* OR corticoster*) in citation or abstract
WH A T ’ S N E W
Last assessed as up-to-date: 28 April 2008.
Date Event Description
23 April 2008 Amended CMSG ID A023-R
23 April 2008 Amended Converted to new review format.
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H I S T O R Y
Protocol first published: Issue 1, 2006
Review first published: Issue 1, 2009
C O N T R I B U T I O N S O F A U T H O R S
CP: main author, involved in all aspects of the review.
DW: text of review, data extraction and analysis.
JW: text of review, data extraction and analysis.
BM: text of review, selection of studies.
D E C L A R A T I O N S O F I N T E R E S T
CP has conducted an RCT (Groningen Hand and Wrist Injection Therapy Trial - HAWITT) assessing the efficacy and safety of
corticosteroid injections for trigger finger, De Quervain’s tenosynovitis, and carpal tunnel syndrome in a primary care population. The
HAWITT trial was sponsored by an unrestricted educational grant from the pharmaceutical company Bristol-Myers Squibb.
S O U R C E S O F S U P P O R T
Internal sources
• Department of General Practice, University Medical Center Groningen, Netherlands.
• EMGO Institute, Vrije Universiteit Medical Center Amsterdam, Netherlands.
External sources
• No sources of support supplied
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenal Cortex Hormones [∗administration & dosage]; Anesthetics, Local [∗administration & dosage]; Lidocaine [∗administration &
dosage]; Randomized Controlled Trials as Topic; Trigger Finger Disorder [∗drug therapy]
MeSH check words
Adult; Humans
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